查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947951

PNH藥物市場：藥物類別、給藥途徑、通路、最終用戶、治療階段、年齡層、全球預測（2026-2032年）

Drugs for PNH Market by Drug Class, Route Of Administration, Distribution Channel, End User, Line Of Therapy, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，陣發性夜間血紅蛋白尿症 (PNH) 治療市場價值將達到 19.2 億美元，到 2026 年將成長至 20.6 億美元，年複合成長率為 9.02%，到 2032 年將達到 35.1 億美元。

關鍵市場統計數據
基準年 2025 19.2億美元
預計年份：2026年 20.6億美元
預測年份 2032 35.1億美元
複合年成長率 (%) 9.02%

本書全面介紹了陣發性睡眠性血尿症治療領域不斷發展的臨床和醫療服務環境，並著重於患者預後。

陣發性睡眠性血尿症是一種罕見的、嚴重影響患者生活的血液疾病，其特徵是補體介導的紅血球破壞、血栓症風險和慢性溶血。對補體生物學分子機制的深入了解，促成了標靶治療藥物的研發，徹底改變了疾病的治療方式，推動了治療策略從反覆輸血和支持治療轉向針對特定補體通路的抑制。這種治療方法的轉變凸顯了不斷完善的治療標準的重要性，治療方法的選擇、給藥途徑和患者意願越來越決定著患者的長期預後和生活品質。

對治療機制、給藥方法和護理模式中模式轉移創新進行觀點的相關人員分析，這些創新正在重塑陣發性睡眠性血紅蛋白尿症（PNH）的治療。

過去幾年，陣發性睡眠性血紅蛋白尿症 (PNH) 的治療格局發生了變革性變化，作用機制不斷創新，給藥途徑日益多樣化，並且更加注重以患者為中心的護理。抑制近端和遠端補體活化的治療方法的出現，拓展了治療選擇，使臨床醫生能夠根據溶血控制、輸血依賴、血栓風險和合併症等因素制定個體化治療方法。這些科學進步與給藥方式的創新相輔相成，例如皮下製劑，這些創新減輕了臨床負擔，並支持患者自我給藥模式，從而提高了便利性和依從性。

評估2025年美國潛在關稅變化對陣發性睡眠性血紅蛋白尿症（PNH）藥物供應鏈、生產本地化、價格波動和患者用藥的影響

2025年公佈的潛在關稅和貿易政策調整將產生策略性變數，影響生物製藥及其活性成分的供應、成本結構和供應鏈韌性。如果新關稅影響進口原料、一次性組件或成品生物製劑，製造商可能面臨生產成本上漲的壓力。這些成本波動可能會影響與支付方和醫療服務提供方的合約行為，促使重新談判定價條款，並加速關於風險分擔和按績效付費合約的討論。

策略性細分分析揭示了藥物類別、給藥途徑、分銷管道、臨床環境、治療方案和年齡層如何驅動臨床和商業策略的差異化。

詳細的市場細分框架揭示了藥物類別、給藥途徑、分銷管道、終端用戶類型、治療方案和年齡層等因素的不同市場動態，這些因素共同影響著商業和臨床策略。在各類藥物中，市場可區分近端補體抑制劑和末端補體抑制劑。前者著重於抑制C5上游活化的藥物，而後者則包括已上市的靶向C5的單株抗體，這些抗體的給藥間隔和輸注要求各不相同。臨床醫師會考慮這些作用機制的差異以及患者的個別特徵，以指南藥物轉換或劑量增加的決策。

對美洲、歐洲、中東和非洲以及亞太地區PNH（陣發性夜間血紅蛋白尿症）治療普及的監管預期、支付方趨勢和治療模式進行區域比較分析

區域趨勢對監管路徑、報銷框架和醫療服務模式有著深遠的影響，進而塑造治療方法的引進和應用。在美洲，監管核准和已建立的專科醫療網路促進了新型生物製藥的快速普及，而支付方的談判則往往側重於價值論證和准入管理協議。該地區居家照護和專科藥房解決方案的使用也在不斷增加，這減輕了醫療機構的負擔，提高了患者的便利性，並且正在建立專家中心來支持複雜病例的管理。

對企業策略（臨床差異化、生產韌性和服務夥伴關係）如何決定PNH治療領域的競爭地位進行了深入評估。

在陣發性睡眠性血紅素尿症（PNH）領域，各公司的策略體現了在臨床差異化、給藥方式創新、生產規模和下游支援服務等方面的不同重點。成熟的C5標靶療法開發商利用長期安全性數據和最佳化的給藥間隔來維持醫療系統的信任，而專注於近端補體抑制的新興參與企業則強調溶血控制方面的機制優勢和皮下給藥的便利性。這種差異化為那些能夠展現卓越治療效果並顯著改善患者用藥體驗的平台創造了明顯的機會。

針對開發人員和商業領袖的具體且全面的建議，旨在加速PNH治療領域的應用，降低風險，並保障病患的治療權益。

為確保在陣發性睡眠性血紅蛋白尿症 (PNH) 領域持續獲得認可，產業領導者應優先考慮整合臨床開發、供應鏈韌性和支付方合作的策略。首先，應調整臨床項目，以產生強調療效比較、長期安全性和患者報告結局的證據，並直接符合支付方和臨床醫生的決策標準。同時，投資真實世界證據平台可以增強價值提案，並縮短臨床實務與藥品目錄決策流程之間的回饋週期。

對混合調查方法進行透明的解釋，該方法結合了相關人員訪談、文獻綜述和情境分析，以支持切實可行的策略結論。

本分析結合了第一手和第二手研究，全面涵蓋了臨床、商業性和政策方面。第一手研究包括對臨床專家、支付方以及輸液中心和專科藥房的營運負責人進行結構化訪談，並輔以製藥公司揭露的資訊和監管文件。第二手研究引用了同行評審文獻、臨床試驗註冊資訊和已發布的監管決策，以闡明治療方案、安全性考量和適應症的差異。

一份權威的綜合分析報告，重點闡述了將治療創新轉化為持續的患者可及性和系統性價值所需的關鍵策略重點。

目前陣發性睡眠性血紅蛋白尿症 (PNH) 的治療環境呈現出顯著的臨床進展、不斷演變的醫療服務模式以及日益複雜的商業性和政策特徵，這要求我們採取靈活、循證的策略，並全面考慮這些因素。補體抑製作用機制的多樣化和更人性化的給藥方式的出現，雖然改善了臨床選擇，但也需要各方協作，共同推進循證實踐、與支付方談判以及服務模式的重塑。能夠將臨床差異化、卓越營運和符合支付方利益的價值論證相結合的相關人員，將更有可能取得成功。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按藥物類別分類的 PNH 藥物市場

  • 近端補體抑制劑
  • 末端補體抑制劑
    • Eculizumab
    • Ravulizumab

9. 按給藥途徑分類的 PNH 藥物市場

  • 靜脈注射
  • 皮下注射

10. 按分銷管道分類的 PNH 藥物市場

  • 居家輸液
  • 醫院藥房
  • 專科藥房

第11章 按最終用戶分類的 PNH 藥物市場

  • 診所
  • 居家照護
  • 醫院

12. 按治療階段分類的 PNH 藥物市場

  • 一線治療
  • 二級治療

13. 按年齡層別分類的 PNH 藥物市場

  • 成人版
  • 兒童
  • 老年人

14. 按地區分類的PNH藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 按組別分類的 PNH 藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國PNH藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國陣發性睡眠性血紅素尿症（PNH）藥物市場

第18章：中國的陣發性睡眠性血紅素尿症（PNH）藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • UCB SA
Product Code: MRR-4F7A6D4FB6A1

The Drugs for PNH Market was valued at USD 1.92 billion in 2025 and is projected to grow to USD 2.06 billion in 2026, with a CAGR of 9.02%, reaching USD 3.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.92 billion
Estimated Year [2026] USD 2.06 billion
Forecast Year [2032] USD 3.51 billion
CAGR (%) 9.02%

Comprehensive introduction to the evolving clinical and care delivery landscape for paroxysmal nocturnal hemoglobinuria therapies with focus on patient outcomes

Paroxysmal nocturnal hemoglobinuria is a rare, life-altering hematologic disorder driven by complement-mediated red blood cell destruction, thrombosis risk, and chronic hemolysis. Advances in molecular understanding of complement biology have translated into targeted therapeutics that fundamentally alter disease management, shifting care from repeated transfusions and supportive measures toward pathway-specific inhibition. This therapeutic transition underscores an evolving standard of care in which treatment choice, route of administration, and patient preference increasingly determine long-term outcomes and quality of life.

Against this clinical backdrop, stakeholders must navigate a complex interplay of clinical efficacy, administration logistics, payer negotiation, and patient support needs. Recent approvals and label expansions have broadened treatment options, introducing varying pharmacologic mechanisms and delivery modalities that influence adherence and resource utilization. Consequently, clinicians, payers, and manufacturers are re-evaluating care pathways, diagnostic workflows, and service models to optimize value for patients while managing constrained health system budgets.

The introduction of therapies that target different nodes of the complement cascade has also catalyzed new research directions and commercial strategies. As the field matures, real-world evidence and long-term safety data will be decisive in shaping prescribing patterns and formulary decisions. Therefore, a nuanced understanding of clinical profiles, administration trade-offs, and system-level implications is essential for any organization aiming to participate successfully in the PNH treatment landscape.

Detailed analysis of paradigm-shifting innovations in therapeutic mechanisms, delivery modalities, and care models reshaping PNH management across stakeholders

Over the past several years, the PNH treatment landscape has undergone transformative shifts driven by mechanistic innovation, route-of-administration diversification, and a stronger emphasis on patient-centric care. The arrival of therapies that inhibit complement activation at proximal and terminal targets has increased therapeutic choice, enabling clinicians to tailor approaches based on hemolysis control, transfusion dependence, thrombotic risk, and comorbidities. These scientific advances are complemented by delivery innovations, such as subcutaneous formulations, which reduce clinic burden and support self-administration models that improve convenience and adherence.

Concurrently, healthcare systems have accelerated adoption of home-based care pathways, leveraging home infusion and specialty pharmacy services to lower institutional resource utilization and improve patient experience. Payers and providers are increasingly demanding robust real-world outcomes and pharmacoeconomic data to justify formulary placements, driving manufacturers to invest in post-approval evidence generation and value demonstration. Additionally, the competitive environment is prompting lifecycle management strategies, including dosing interval optimization and patient support programs, to differentiate products beyond primary efficacy.

Finally, integration of diagnostics and longitudinal monitoring is enhancing therapeutic decision-making, with biomarkers and clinical metrics informing escalation or switching strategies. Together, these shifts are moving PNH care from episodic, hospital-centered interventions toward sustained, individualized management paradigms that emphasize long-term safety, sustained hemolysis control, and improved quality of life.

Assessment of how potential United States tariff shifts in 2025 could influence supply chains, manufacturing localization, pricing dynamics, and patient access for PNH therapies

Potential tariff actions and trade policy adjustments announced for 2025 create strategic variables that can influence availability, cost structures, and supply chain resilience for biologics and their active ingredients. If new duties affect imported raw materials, single-use components, or finished biologic products, manufacturers may experience upward pressure on production costs. Those cost dynamics can, in turn, influence contracting behavior with payers and providers, prompting renegotiations of pricing terms and potentially accelerating discussions around risk-sharing or outcome-based agreements.

In response to tariff-driven uncertainty, manufacturers and contract manufacturing organizations may accelerate localization initiatives, diversify sourcing across multiple regions, or scale domestic capacity to shield critical inputs from cross-border cost volatility. These shifts can improve long-term supply reliability but require capital investment and time to operationalize. Distribution partners and specialty pharmacies will need to reassess inventory strategies and procurement timelines to mitigate short-term disruptions, while hospitals and clinic systems may adjust formulary choices to maintain budget neutrality.

For patients, the principal risks relate to access and affordability. Payer responses may include narrower preferred product listings, increased utilization management, or expanded emphasis on biosimilar or lower-cost alternatives where available. To preserve patient access, manufacturers can expand patient support programs and collaborate with providers to maintain continuity of care through home infusion or specialty pharmacy services. Policymakers and industry leaders should therefore view tariff impacts through a multi-stakeholder lens, aligning supply chain resilience measures with patient access safeguards and evidence-generation commitments.

Strategic segmentation analysis revealing how drug class, administration route, distribution channel, care setting, therapy line, and age cohort drive differentiated clinical and commercial strategies

A granular segmentation framework reveals differential dynamics across drug classes, routes of administration, distribution channels, end user types, lines of therapy, and age groups that collectively shape commercial and clinical strategies. Within drug class, the market distinguishes between proximal complement inhibitors and terminal complement inhibitors; the former focuses on agents that interrupt activation upstream of C5, while the latter includes long-established C5-targeted monoclonal antibodies with distinct dosing intervals and infusion requirements. Clinicians weigh these mechanistic differences alongside individual patient characteristics to guide switching and escalation decisions.

Route of administration is another critical determinant, with intravenous therapies typically administered in clinic or infusion center settings, and subcutaneous options enabling self-administration or home-based care. Distribution channel choices intersect directly with administration modalities: home infusion services, hospital pharmacies, and specialty pharmacies each offer different trade-offs in terms of adherence support, reimbursement complexity, and operational overhead. End users including clinics, home care providers, and hospitals require tailored service and training models to deliver therapies safely and effectively, particularly when transitioning patients to home-based administration.

Line-of-therapy considerations influence initial prescribing behavior and subsequent treatment sequencing, with first-line and subsequent-line contexts presenting distinct evidence thresholds and payer expectations. Age group segmentation between adult and pediatric patients introduces further nuance, as pediatric care settings demand additional safety monitoring, dosing considerations, and long-term outcome data. Together, these intersecting segments inform targeted clinical development, differentiated commercial messaging, and customized support services that optimize uptake and sustained use across patient cohorts.

Comparative regional insights into regulatory expectations, payer dynamics, and care delivery models across the Americas, EMEA, and Asia-Pacific that affect PNH adoption

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and care delivery models, shaping how therapies are adopted and scaled. In the Americas, regulatory approvals and established specialty care networks facilitate relatively rapid uptake of new biologics, while payer negotiation tends to emphasize value demonstration and managed-access agreements. This region also shows growing utilization of home-based services and specialty pharmacy solutions that reduce institutional burden and enhance patient convenience, with concentrated centers of expertise supporting complex case management.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and cost-containment policies result in variable access timelines and formulary decisions. Countries with centralized health technology assessment processes often require robust comparative and economic evidence before broad adoption, incentivizing manufacturers to invest in region-specific real-world studies and health economic modeling. In contrast, certain markets within the region may adopt accelerated access pathways for high-need rare disease therapies, necessitating tailored pricing and distribution approaches.

The Asia-Pacific region reflects a mix of rapidly modernizing healthcare infrastructure and diverse payer maturity. Urban centers are increasingly capable of deploying advanced therapeutic delivery models, while broader geographic access challenges persist in less resourced areas. Manufacturers looking to expand presence here must navigate complex regulatory submissions, local manufacturing considerations, and partnership models to ensure sustainable supply and appropriate patient support services across national markets.

Insightful assessment of how company strategies in clinical differentiation, manufacturing resilience, and service partnerships determine competitive positioning in PNH therapeutics

Company strategies in the PNH space reflect differentiated priorities around clinical differentiation, delivery modality innovation, manufacturing scale, and downstream support services. Established developers of C5-directed therapies have leveraged long-term safety datasets and dosing interval optimization to maintain healthcare system confidence, while newer entrants focusing on proximal complement inhibition emphasize mechanistic advantages in hemolysis control and the convenience of subcutaneous administration. This divergence creates clear opportunities for platforms that can demonstrate superior patient-relevant outcomes or materially improved administration experiences.

Additionally, several companies are investing in manufacturing resilience and supply chain redundancy to mitigate disruption risk, particularly given the complexity of biologics production. Partnerships with specialty pharmacies and home infusion providers are increasingly central to commercialization plans, as they facilitate patient onboarding, adherence monitoring, and coordination with payers. Firms pursuing lifecycle management strategies are also developing patient support programs and digital adherence tools to enhance long-term retention and capture real-world effectiveness data.

Finally, competitive positioning is shaped by regulatory strategy and evidence generation. Organizations that proactively generate head-to-head, real-world, and long-term safety data can influence formulary decisions and prescribing norms. Strategic collaborations, whether through licensing, co-promotion, or manufacturing alliances, remain a pragmatic route to broaden access, optimize cost structures, and accelerate diffusion in complex global markets.

Concrete and integrated recommendations for developers and commercial leaders to accelerate adoption, de-risk launches, and protect patient access in the PNH treatment landscape

Industry leaders should prioritize integrated strategies that unite clinical development, supply chain resilience, and payer engagement to secure sustained adoption in the PNH space. Begin by aligning clinical programs to generate evidence that speaks directly to payer and clinician decision criteria, emphasizing comparative effectiveness, long-term safety, and patient-reported outcomes. Parallel investments in real-world evidence platforms will strengthen value propositions and shorten the feedback loop between clinical practice and formulary decision-making.

Operationally, companies should pursue manufacturing diversification and strategic partnerships with contract manufacturers and specialty pharmacies to reduce single-source risk and enable flexible supply responses. Embedding robust patient support services-including initiation assistance for home administration, adherence monitoring, and financial navigation-will protect continuity of care and maintain favorable real-world performance measures. Moreover, exploring innovative contracting models such as outcomes-based agreements can align incentives with payers and mitigate upfront reimbursement risks while showcasing long-term value.

Finally, leadership teams should invest in cross-functional launch readiness that integrates regulatory, medical affairs, market access, and commercial functions. Tailored education for prescribers and infusion centers, clear transitions to home care pathways, and proactive pediatric strategy development will collectively improve uptake and patient outcomes. These actionable steps create a resilient, patient-centered approach that balances innovation with practical delivery and payer realities.

Transparent explanation of the mixed-methods research approach combining stakeholder interviews, literature synthesis, and scenario analysis to underpin practical strategic conclusions

This analysis synthesizes primary and secondary research components to ensure comprehensive coverage of clinical, commercial, and policy dimensions. Primary inputs include structured interviews with clinical experts, payers, and operational leaders across infusion centers and specialty pharmacies, complemented by pharmaceutical company disclosures and regulatory documentation. Secondary research draws on peer-reviewed literature, clinical trial registries, and public regulatory decisions to contextualize therapeutic profiles, safety considerations, and label differentials.

Analytical methods incorporate comparative mechanism assessment, route-of-administration impact modeling on care delivery workflows, and scenario planning for policy variables such as trade measures and reimbursement shifts. Segmentation mapping evaluated how drug class, administration route, distribution channels, care settings, therapy line, and age cohort interact to influence adoption and service needs. The methodology also includes a qualitative synthesis of patient pathway implications and a risk assessment of supply chain vulnerabilities, with limitations clearly articulated where evidence is presently limited or evolving.

Triangulation across data sources and stakeholder perspectives strengthens the robustness of conclusions, while sensitivity analyses of key assumptions provide clarity on which variables most materially affect strategic choices. This layered approach ensures the report supports pragmatic decision-making for clinical development, market access planning, and operational execution in a rapidly changing therapeutic area.

Conclusive synthesis highlighting the essential strategic priorities required to convert therapeutic innovation into sustained patient access and system-aligned value

The current PNH therapeutic environment is characterized by meaningful clinical advances, evolving care delivery models, and intensifying commercial and policy complexities that together require agile and evidence-driven strategies. Mechanistic diversification in complement inhibition and the shift toward more patient-friendly administration modalities have improved clinical options, but they also demand coordinated approaches to evidence generation, payer negotiation, and service delivery redesign. Stakeholders that integrate clinical differentiation with operational excellence and payer-aligned value demonstration will be best positioned to succeed.

Practical imperatives include investing in real-world evidence to validate long-term outcomes, strengthening manufacturing and distribution resilience to protect access, and tailoring patient support services to sustain adherence and optimize real-world effectiveness. Regulatory heterogeneity across regions underscores the need for targeted market entry strategies and adaptive pricing approaches that respect local reimbursement norms. Collectively, these priorities form a roadmap for translating therapeutic innovation into sustainable access and improved patient outcomes.

In closing, the interplay of science, service, and systems thinking will determine which therapies achieve broad adoption and which operational models deliver scalable patient benefits. Stakeholders who act decisively to align clinical value with delivery feasibility and payer expectations will shape the next chapter of PNH care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for PNH Market, by Drug Class

  • 8.1. Proximal Complement Inhibitors
  • 8.2. Terminal Complement Inhibitors
    • 8.2.1. Eculizumab
    • 8.2.2. Ravulizumab

9. Drugs for PNH Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Subcutaneous

10. Drugs for PNH Market, by Distribution Channel

  • 10.1. Home Infusion
  • 10.2. Hospital Pharmacy
  • 10.3. Specialty Pharmacy

11. Drugs for PNH Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Drugs for PNH Market, by Line Of Therapy

  • 12.1. First-Line
  • 12.2. Subsequent-Line

13. Drugs for PNH Market, by Age Group

  • 13.1. Adult
  • 13.2. Pediatric
  • 13.3. Geriatric

14. Drugs for PNH Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drugs for PNH Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drugs for PNH Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Drugs for PNH Market

18. China Drugs for PNH Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Alexion Pharmaceuticals, Inc.
  • 19.7. Amgen Inc.
  • 19.8. Apellis Pharmaceuticals, Inc.
  • 19.9. AstraZeneca PLC
  • 19.10. Biogen Inc.
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Bristol Myers Squibb Company
  • 19.13. Catalyst Biosciences, Inc.
  • 19.14. Ionis Pharmaceuticals, Inc.
  • 19.15. Janssen Pharmaceuticals, Inc.
  • 19.16. Merck & Co., Inc.
  • 19.17. Novartis AG
  • 19.18. Pfizer Inc.
  • 19.19. Ra Pharmaceuticals
  • 19.20. Regeneron Pharmaceuticals, Inc.
  • 19.21. Roche Holding AG
  • 19.22. Sanofi
  • 19.23. Swedish Orphan Biovitrum AB
  • 19.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR PNH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR PNH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PROXIMAL COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR PNH MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR PNH MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR PNH MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR PNH MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR PNH MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR PNH MARKET SIZE, BY SUBSEQUENT-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUGS FOR PNH MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUGS FOR PNH MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUGS FOR PNH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DRUGS FOR PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUGS FOR PNH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GCC DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. G7 DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. G7 DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. G7 DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. NATO DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. NATO DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. NATO DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DRUGS FOR PNH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA DRUGS FOR PNH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA DRUGS FOR PNH MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA DRUGS FOR PNH MARKET SIZE, BY TERMINAL COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA DRUGS FOR PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA DRUGS FOR PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA DRUGS FOR PNH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA DRUGS FOR PNH MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA DRUGS FOR PNH MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)